title: Haematological cancer: Bortezomib in MCL--new standard of care or just another option?
authors.affiliation: Department of Medicine III, University Hospital, Ludwig-Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Dreyling
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069286:Bortezomib / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D059039:Standard of Care; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D000069286:Bortezomib; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone